Guardant Health, Inc. (GH)
Automate Your Wheel Strategy on GH
With Tiblio's Option Bot, you can configure your own wheel strategy including GH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GH
- Rev/Share 6.2484
- Book/Share -2.0246
- PB -19.0408
- Debt/Equity -5.2091
- CurrentRatio 4.1064
- ROIC -0.4079
- MktCap 4775882400.0
- FreeCF/Share -2.4612
- PFCF -15.6652
- PE -11.4638
- Debt/Assets 0.9718
- DivYield 0
- ROE 3.6851
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GH | Mizuho | -- | Outperform | -- | $55 | April 10, 2025 |
| Initiation | GH | Barclays | -- | Overweight | -- | $60 | Jan. 23, 2025 |
News
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. Fea.
Read More
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health's list is more than a personal honor,” said AmirAli Talasaz, Guardant Health co-CEO. “It is a recognition of the incredible technology that our Guardant team has buil.
Read More
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option awards to purchase 19,295 shares of its common stock to two new non-executive employees with a grant date of May 2.
Read More
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Tycho Peterson - Jefferies Bill Bonello - Craig-Hallum Subbu Nambi - Guggenheim Partners Puneet Souda - Leerink Partners Dan Leonard - UBS Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings …
Read More
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
Published: March 11, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening.
Read More
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr.
Read More
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Read More
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Published: February 21, 2025 by: Benzinga
Sentiment: Positive
On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.
Read More
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - …
Read More
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Guardant Health to Participate in Upcoming Investor Conferences
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim.
Read More
About Guardant Health, Inc. (GH)
- IPO Date 2018-10-04
- Website https://guardanthealth.com
- Industry Medical - Diagnostics & Research
- CEO Dr. Helmy Eltoukhy Ph.D.
- Employees 1999